Can sibutramine alter systemic blood pressure in obese patients? Systematic review and meta-analysis

Sao Paulo Medical Journal

Volumn 126, Issue 6, 2008, Pages 342-346

  de Lemos Jr , Hernani Pinto ^a,d   Attalah, Álvaro Nagib ^a,b,c   de Lemos, André Luis Alves ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Brazilian Cochrane Center   (Brazil)

^c School of Medical Sciences Santa Casa de São Paulo   (Brazil)

^d Associação Paulista de Medicina ^*  (Brazil)

Author keywords

Anti obesity agents; Body mass index; Hypertension; Obesity; Overweight

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; PLACEBO; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BLOOD PRESSURE; BODY MASS; CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GENETIC HETEROGENEITY; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; META ANALYSIS; OBESITY; OUTCOME ASSESSMENT; PREVALENCE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

EID: 70349572344     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-31802008000600010     Document Type: Review

References (31)

1. Hodge AM, Zimmet PZ. The epidemiology of obesity. Baillieres Clin Endocrinol Metab. 1994;8(3):577-99.
2. Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J Clin Endocrinol Metab. 1982;54(2):254-60.
3. Larsson B, Svärdsudd K, Welin L, Wilhelmsen L, Björntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed). 1984;288(6428):1401-4.
4. Berne C. Insulin resistance in hypertension - a relationship with consequences? J Intern Med Suppl. 1991;735:65-73.
5. Moan A, Nordby G, Rostrup M, Eide I, Kjeldsen SE. Insulin sensitivity, sympathetic activity, and cardiovascular reactivity in young men. Am J Hypertens. 1995;8(3):268-75.
6. Hall JE. Louis K. Dahl Memorial Lecture. Renal and cardiovascular mechanisms of hypertension in obesity. Hypertension. 1994;23(3):381-94.
7. Hall JE, Zappe DH, Alonso-Galicia M, Granger JP, Brands MW, Kassab SE. Mechanisms of obesity-induced hypertension. News Physiol Sci. 1996;11:255-61. [Abstract] Available from: http://physiologyonline.physiology.org/cgi/content/abstract/11/6/255. Accessed in 2008 (Oct 7).
8. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord. 1999;23(10):1016-24.
9. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000;356(9248):2119-25.
10. Seagle HM, Bessesen DH, Hill JO. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res. 1998;6(2):115-21.
11. Gundlah C, Martin KF, Heal DJ, Auerbach SB. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor. J Pharmacol Exp Ther. 1997;283(2):581-91.
12. Clarke M, Oxman AD, editors. Cochrane Reviewers' Handbook 4.1.5 [updated April 2002]. In: The Cochrane Library, Issue 2. Oxford: Updated Software; 2002.
13. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408-12.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
15. Clarke M, Oxman AD, editors. Cochrane Reviewers' Handbook 4.0. In: Review Manager (RevMan) [Computer program]. Version 4.0. Oxford, England: The Cochrane Collaboration; 1999.
16. Hazenberg BP. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology. 2000;94(3):152-8.
17. Fanghänel G, Cortinas L, Sánchez-Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord. 2000; 24(2):144-50.
18. Faria AN, Ribeiro Filho FF, Lerario DD, Kohlmann N, Ferreira SR, Zanella MT. Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. Arq Bras Cardiol. 2002;78(2):172-80.
19. Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2000;2(3):175-87.
20. Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab. 2005;90(3):1460-5.
21. Sramek JJ, Leibowitz MT, Weinstein SP, et al. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. J Hum Hypertens. 2002;16(1):13-9.
22. Zannad F, Gille B, Grentzinger A, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J. 2002;144(3):508-15.
23. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 1999;106(2):179-84.
24. Cuellar GE, Ruiz AM, Monsalve MC, Berber A. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res. 2000;8(1):71-82.
25. McMahon FG, Weinstein SP, Rowe E, et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens. 2002;16(1):5-11.
26. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab. 2000;2(2):105-12.
27. McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med. 2000;160(14):2185-91.
28. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin. 2005;21(3):457-68.
29. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2004;(3):CD004094.
30. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194-9.
31. Horvath K, Jeitler K, Siering U, et al. Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Arch Intern Med. 2008;168(6):571-80.